Ulrich von Grünhagen

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +10

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

Lymphoid Neoplasia, Rituximab Versus Chop, Oncology +10

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 439 citations · Full text

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

Mathias Rummel, Kai Uwe Chow, T. Karakas et al. · European Journal of Cancer · 2002 · 44 citations

Lymphoid Neoplasia, Oncology, Medicine +7

Efficacy and Tolerability of Alemtuzumab (CAMPATH-1H) in the Salvage Treatment of B-Cell Chronic Lymphocytic Leukemia—Change of Regimen Needed?

Kathrin Rieger, Ulrich von Grünhagen, Thomas Fietz et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2003 · 30 citations

Mixed-phenotype Acute Leukemia, Regimen Needed, Immunology +16